Mark A. Velleca - 14 Feb 2024 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
PRESIDENT & CEO, Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
14 Feb 2024
Net transactions value
$0
Form type
4
Filing time
15 Feb 2024, 17:35:28 UTC
Previous filing
18 Sep 2023
Next filing
31 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +537,000 $0.000000 537,000 14 Feb 2024 Common Stock 537,000 $4.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter.